Modulation of Cox-1, 5-, 12- and 15-Lox by Popular Herbal Remedies Used in Southern Italy Against Psoriasis and Other Skin Diseases

Ammar Bader, Francesca Martini, Guillermo R. Schinella, Jose L. Rios and Jose M. Prieto

1Department of Pharmacognosy, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia
2Departament de Farmacologia, Facultat de Farmacia, Universitat de Valencia, 46100, Burjassot, Valencia, Spain
3Catedra de Farmacologia Basica, Facultad de Ciencias Medicas, Universidad Nacional de La Plata, CIC Provincia de Buenos Aires, 1900, La Plata, Buenos Aires, Argentina
4Centre for Pharmacognosy and Phytotherapy, University College London School of Pharmacy, WC1N 1AX, London, United Kingdom

* Correspondence to: Jose M. Prieto, Centre for Pharmacognosy and Phytotherapy, University College London School of Pharmacy, 29-39 Brunswick Square, WC1N 1AX London, United Kingdom. E-mail: j.prieto@ucl.ac.uk

INTRODUCTION

Psoriasis is one of the most important chronic pathologies of the skin, affecting roughly 1–3% of the world’s population. Apart from being usually recurrent, psoriasis can often be very debilitating, with 5–10% of all patients developing psoriatic arthritis, which causes inflammation and swelling in the hands, feet and large joints (DiSepio et al., 1999). As the skin is the most accessible and largest of our organs, remedies for the many dermatological disorders have been well developed—and are consistently preserved—within traditional health systems.

Ethnobotanical investigations in Sicily reported the use of several herbal remedies for the relief of psoriasis symptoms. These included ‘biancarrassina’ (Acanthus mollis L., Acanthaceae), ‘millefoglio’ (Achillea spp, Asteraceae), ‘erva bianca’ (Artemisia arborescens L., Asteraceae) and ‘vruca’ (Inula viscosa (L.) Aiton, Asteraceae). These plants are collected during spring time and used to make a decoction by crushing and soaking their aerial parts in cold water and untreated wine (Amenta et al., 2000).

The use of A. mollis and Achillea ligustica is also reported as a first choice herbal remedy for skin diseases in zones of Sardinia (Bruni et al., 1997) and the decoction of the roots of I. viscosa is used in Calabria—under the local name of ‘spulitru’—for the relief of skin irritation of allergic origin (Passalacqua et al., 2007).

Eicosanoids have been assigned an important role in inflammatory skin diseases such as psoriasis and atopic dermatitis. Neutrophils rapidly migrate into the inflamed epidermis and get into close contact with the keratinocytes releasing leukotriene A₄ (LTA₄) into the extracellular space. From this substrate, transcellular leukotriene synthesis may therefore be an important mechanism by which the human epidermis can contribute significantly to leukotriene B₄ (LTB₄) formation. In addition, 12(S)-hydroxy-5Z,8Z,10E,14Z-tetraenoic acid (12(S)-HETE) has been shown as one of the main eicosanoids formed by the epidermis and has been detected in large quantities in human psoriatic scales (Iversen and Kragballe, 2000). Thus, the putative activity of extracts prescribed for such disorders may arise—at least in part—from their ability to inhibit—directly or indirectly—the activity of the enzymes responsible for their synthesis.

Some aspects of the phytochemistry and pharmacology of these species have been already published elsewhere, but to the best of our knowledge, there is not a comparative assessment of their actions on COX and LOX pathways in intact pro-inflammatory mammalian cells yet. We therefore aim to assess the in vitro effect...
of these herbal remedies on the release of LTB₄, other major pro- and anti-inflammatory eicosanoids and the activation of the nuclear factor kappaB (NFκB). Their antioxidant activity was tested just to rule out possible unspecific inhibition of COX and LOX enzymes, which are redox-sensitive enzymes. We hope in this manner to gain insight into the possible biochemical mechanisms of these extracts that justify their popular antipsoriatic use in Southern Italy. This could facilitate the development of rational formulations in herbal medicinal products against inflammatory topical conditions.

**MATERIAL AND METHODS**

**Chemicals.** Boswellia serrata H15® resin was obtained from Gufic Chemicals (India). It consists on a standardised extract rich in the 5-LOX inhibitor acetyl-11-keto-β-boswellic acid (Glaser et al., 1999). All other chemicals were of the highest available analytical grade and purchased from Sigma-Aldrich (USA) or from Merck (Germany). Solvents (HPLC grade) were provided by JT Baker (The Netherlands) and Fisher (UK).

**Biological material.** Buffy coats were obtained from the Centre de Transfusions de la Generalitat Valenciana (Valencia, Spain). Wistar rats, each 250–300 g, were provided by the animal facility of the Faculty of Pharmacy (University of Valencia). Housing conditions and all in vivo experiments were approved by the institutional Ethical Committee of the Faculty of Pharmacy, University of Valencia (Spain), according to the guidelines established by the European Union on Animal Care (CEE Council 86/609).

**Plant material.** The leaves of A. mollis L. (Acanthaceae), A. ligustica L. (Asteraceae), A. arborescens L. (Asteraceae) and the flowering aerial parts of Inula viscosea (L.) Aiton (Asteraceae) were collected and identified by one of the co-authors (A.B.) in Novara di Sicilia (Messina, Italy, Spring 1998). Voucher specimens (references 3563–Pharm, 3982-Pharm 4027) were deposited at the herbarium of the Dipartimento di Chimica Bioorganica e Biofarmacia, Università degli Studi di Pisa (Italy). Milk thistle (Silybum marianum (L.) of pharmacopeial grade was supplied by Professor J. B. Peris (Department of Botany, Faculty of Pharmacy, University of Valencia, Spain).

**Preparation of extracts.** The powdered dried drugs were macerated in methanol (20 g in 400 mL, 24 h). The solvent was evaporated under vacuum, and the residues were lyophilised. The dried methanolic extract of A. ligustica (2.70 g) was dissolved in 10% aqueous methanol and partitioned with solvents of increasing polarity (n-hexane, dichloromethane, ethyl acetate and n-butanol) yielding four fractions (M = 622, 695, 165 and 380 mg, respectively).

For the in vitro assays, the plant extracts were dissolved in dimethyl sulfoxide (DMSO) by vigorous shaking for 30 min. Non soluble parts were removed by centrifugation (10 min, 10000 ×g), and the stock solutions were adjusted to 40 μg/mL. The final concentration of DMSO was 0.05% in all incubations including controls.

**Solid phase extraction (SPE) and analytical HPLC system.** Solid phase extraction (SPE) was performed with Licrolut® columns C18, 100 mg, 1 mL (Merck) attached to a 12-port vacuum manifold Visiprep® (Supelco). HPLC-DAD analysis of eicosanoids was performed on a Merck Hitachi system consisting on an Intelligent Pump L-6200, Diode Array Detector L-7455, Auto Sampler L-7200, precolumn Lichrospher® C18 (4 × 4 mm, 5 μm, Merck), column Lichrospher® C18 (250 × 4 mm, 5 μm Merck) and software HSM-7000. Elution conditions were as follows: flow rate 1 mL/min; 0–27 min, 100% A; 27.1–27.6 min, 0% A; 27.7–40 min, 100% A; Eluents MeOH/H₂O (74:26) + trifluoroacetic acid (0.007%) (A) and MeOH (B). All plant extracts were fingerprinted using a Waters system consisting on a series 600 pump, Series 990 Diode array, column Phenomenex® C18 (250 × 4 mm, 5 μm), and processed using the Millenium software. Chromatograms and elution conditions for each one are available as supplementary materials.

**Cytotoxicity assay.** The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay described by Mosmann (1983) was used as a criterion of cytotoxicity. Human leukocytes (1 × 10⁶ cells) were preincubated at 37°C for 30 min in Dulbecco’s phosphate buffered saline (PBS) pH 7.4, containing the extracts at 200 μg/mL. The dark blue formazan coloured metabolite was dissolved in DMSO in an ultrasonic bath and measured at 490 nm.

**Assay of 5-LO activity.** Rat polymorphonuclear leukocytes (PMNL) were harvested by intraperitoneal injection of glycogen. The elicited PMNL (5 × 10⁶) were incubated and processed as described by Safayhi et al. (1995). Leukotriene B₄ (LTB₄) was selectively extracted from the cell supernatants by SPE and quantified by HPLC-DAD with the help of the internal standard Prostaglandin B₂ (PGB₂).

**Assay of COX-1, 12-, and 15-LOX activities.** Human platelets were obtained from human buffy-coats. A differential counting was done using a Coulter Counter (Sysmex D-800, Kobe, Japan). Their viability was assessed by fluorescence microscopy (Nikon, Japan) staining with acridine orange/ethidium bromide. Aliquots of 80 × 10⁶ platelets were incubated and processed as described by Safayhi et al. (1992). Absolute quantification of 12(S)-hydroxy-5Z,8E,10E-heptadecatrienoic acid (12(S)-HHTrE) from the COX-1 pathway, 12(S)-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid (12(S)-HETE) from the 12-LOX pathway and 15(S)-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid (5(S)-HETE) acid was performed by means of internal standards. Phospholipase A₂ (PLA₂) impairment can be also indirectly estimated in this model as discussed in the next section.

**Assay of the activation of the NFκB.** HeLa-luc cells, consisting on HeLa cells expressing a luciferase reporter gene controlled by the IL-6 promoter, were kindly provided by Prof. M. Heinrich (UCL, School of Pharmacy). IL-6 is one of the target genes for activated NFκB. Therefore, the chemiluminescence produced by luciferase can be measured as an IL-6 dependent measurement.
of the activation or inhibition of NFκB, as described by Bremner et al. (2004).

**Redox properties assays.** For the ABTS•⁺ radical decolorization, 10 μL of a solution of the extracts (10–100 μg/mL) in water was added to 1 mL of ABTS•⁺ solution, and the absorbance at 734 nm was determined after 30 min (Pannala et al., 2001). For the DPPH scavenging assay, 100 μL of a DPPH solution (0.1 μM) was added to 100 μL of a methanolic solution of the extracts. After 30 min the absorbance at 540 nm was measured (Brand-Williams et al., 1995). All incubations were conducted in the dark at room temperature.

**Statistical methods.** Percentages of inhibition are shown as mean ± S.E.M. of three or more independent experiments, and every experiment was performed in duplicate. The inhibition of 5-LOX total activity is expressed as percentages of LTB4 released with respect to the control. Inhibition of COX-1 and 12-LOX activities is expressed as percentages with respect to the control of 12(S)-HHT and 12(S)-HETE, respectively. Linear regressions and statistical evaluation were performed by ANOVA followed by Dunnett’s t-test for multiple comparisons using Graph-Pad InStat 3.0 and Prism 4.0 software. Values with p < 0.05 were considered significant.

**RESULTS**

**Extraction of plant material**

Yields of the extractions were: *A. mollis*, leaves, 24.4%; *A. ligustica*, leaves, 13.5%; *A. arborescens*, leaves, 13.1%; *I. viscosa*, aerial parts, 9.3%.

**Cytotoxicity**

None of the extract resulted cytotoxic to rat PMNs or human platelets at the assayed doses as per the MTT assay (data not shown).

**Effects on 5-LOX activity**

When tested at 200 μg/mL, the methanolic extracts of *A. ligustica, A. arborescens* and *I. viscosa* completely inhibited the LTB4 biosynthesis (100%) as evidenced by the absence of any significant peak corresponding to LTB4. *S. marianum* extract achieved a 61% of reduction only (p 0.001). *A. mollis* methanol extract resulted the less active (30%) but was still highly significant (p < 0.001).

Unfortunately, the calculation of the IC50 was only possible for the methanolic extract of *A. ligustica* (IC50 = 49.5 μg/mL) (Fig. 1A) because the secondary metabolites of *A. arborescens* and *I. viscosa* co-eluted with the internal standard (PGB2). However, their IC50 are lower than 100 μg/mL, thus resulting more active than *S. marianum* (IC50 = 147.8 μg/mL). The IC50 for *A. ligustica* is comparable to the commercial product H15©, an extract enriched in boswellic acids that are specific, non redox inhibitors of LTB4 biosynthesis (Glaser et al., 1999; Safayhi et al., 1992).

When *A. ligustica* was further subjected to a liquid–liquid fractionation, the resulting n-hexane, dichloromethane and ethyl acetate fractions also had inhibitory effect on the LTB4 biosynthesis with IC50 of 9.6 μg/mL, 20.3 μg/mL and 68 μg/mL, respectively (Fig. 1B), while the n-butanol fraction was inactive at the maximum tested concentration of 200 μg/mL.

**Effects on COX-1, 12- and 15-LOX activities**

The crude plant extracts were tested at 200 μg/mL in human platelets (n = 3) (Fig. 2). They all resulted potent inhibitors of the COX-1 activity measured as 12(S)-HHT and 12(S)-HETE. We also noticed that extracts of *A. ligustica* and *A. mollis* significantly enhanced the biosynthesis of 15(S)-HETE in human platelets. However, none was able to inhibit 12-LOX activity. We used piroxicam (50 ± 4% inhibition at 6.25 μM) for COX-1 activity and nordihydroguaiaretic acid (NDGA) for COX-1 and 12-LOX activity (46 ± 3% and 59 ± 8% inhibition at 10 μM, respectively) as reference drugs. Because our experimental model does not add exogenous arachidonic acid (AA), an impairment of the PLA2 activity can be ruled out.

**Antioxidant activity**

The IC50 values of the free radical scavenger activity of the extracts ranged 71–83 μg/mL in the ABTS•⁺ method (Fig. 3) whilst they were higher than 100 μg/mL in the

© 2014 The Authors. Phytotherapy Research published by John Wiley & Sons Ltd.
DPPH method (data not shown). We consider these values quite modest, and we do not think that antioxidant activities contribute to the in vitro anti-inflammatory properties of these extracts. Gallic acid was used as reference compound (IC50 ABTS = 1.9 μM; IC50 DPPH = 4.7 μM).

Activation of the NFκB

*A. ligustica* (IC50 = 16.7 μg/mL), *A. arborescens* (IC50 = 19.2 μg/mL) and *I. viscosa* (IC50 = 30.4 μg/mL) resulted very active preventing the activation of this important nuclear factor (Fig. 4). On the other hand, *A. mollis* resulted inactive (IC50 ≥ 200 μg/mL). Parthenolide (57 ± 4% inhibition at 5 μM) was used as reference drug.

**DISCUSSION**

The selected popular Italian antipsoriatic herbal medicines are endowed with dual COX-1 and 5-LOX inhibitory activity. The search for dual inhibitory activity in anti-inflammatory medicines is regarded as the next step in the evolution of therapeutic agents in psoriasis, among other chronic conditions (Charlier and Michaux, 2003). These plant extracts did not show any in vitro relevant activity as radical scavengers, which may rule out unspecific antioxidant inhibition of the redox sensitive COX and LOX enzymes.

On the other hand, the activity of the proinflammatory enzyme 12-LOX was not inhibited by any of the plant extracts below 200 μg/mL. Only *A. mollis* had a borderline inhibitory effect on this enzyme, and slightly higher concentrations may well turn off the biosynthesis of 12(S)-HETE. As previously mentioned, 12(S)-HETE is present in psoriatic scales (Iversen and Kragballe, 2000). Human platelets produce 12(S)-HHTrE and 12(S)-HETE from the COX-1 and 12-LOX pathways, respectively, after stimulation with Ca++ and ionophore A23187. In psoriatic epidermis only the platelet-type 12-LOX is detectable (Henke et al., 1986) so this in vitro model is relevant for the screening for antipsoriatic drugs. *A. ligustica* and *A. mollis* extracts enhance the biosynthesis of 15(S)-HETE, an anti-inflammatory eicosanoid (Fig. 2). The synthesis of anti-inflammatory autacoids such as lipoxins and resolvins also depends on the
15-LOX enzyme (Serhan et al., 2008; Sun et al., 2007). The 15-LOX enzyme is a minor pathway in human platelets stimulated with ionophore A23187, and the exogenous or endogenous AA is channelled primarily to the formation of other eicosanoids (Spector et al., 1988). In this context, the overproduction of 15(S)-HETE is likely due to a phenomenon known as shunting, consisting on the channelling of the endogenous AA that is not metabolized by COX-1 and 12-LOX into the 15-LOX pathway. One of the pharmacological effects of such an increase could actually be the enhancement of the anti-inflammatory activity, since 15(S)-HETE is itself an inhibitor of both 12-LOX and PLA₂ activities in human platelets (Spector et al., 1988).

In addition, A. ligustica, A. arborescens and I. viscosa are endowed with NFkB inhibitory activity. This activity has been linked—at least in part—to the presence of sesquiterpene lactones. This nuclear factor is able to inhibit the expression of genes encoding the enzymes responsible for the eicosanoids biosynthesis (Yamamoto and Gaynor, 2004). However, it was demonstrated that intact cell models of eicosanoids biosynthesis using short incubations—similar to those performed in this work—reflect the direct interaction of the secondary metabolites with the arachidonate cascade rather than any effect on the NFkB (Tornhamre et al., 2001). Therefore our overall results are showing a potent, specific and immediate effect of the plant extracts upon the enzymes involved in the arachidonate pathway, which is followed at a later stage by a NFkB inhibitory activity.

We also conducted a comparison of A. ligustica with two antipsoriatic herbal medicines of reference. The use of S. marianum L. across Europe as an antipsoriatic remedy is well documented (Amenta et al., 2000). However, Milk Thistle has been better known as a secular remedy for hepatic disorders in Western phytotherapy, which is underpinned by its antioxidant, radical scavenger, anti-inflammatory and immunostimulant properties (Flora et al., 1998; Luper, 1999). The use of this species as antipsoriatic is believed to be due to its content on silibinin (Dehmlow et al., 1996), a potent inhibitor of LTΒ₄ biosynthesis by leukocytes. In fact, leukotrienes are an important therapeutic target in psoriasis (Voorhees, 1983). In this regard the resin of B. serrata L. and its active principle acetyl-11-keto boswellic acid (AKBA), a known potent, direct, non-redox 5-LOX inhibitor (Safayhi et al., 1995), is another herbal remedy of Ayurveda origin with an enormous potential in the therapy of psoriasis (Ammon et al., 1993; Wang et al., 2009). In terms of the inhibition of leukotriene biosynthesis, A. ligustica crude extract resulted more active than S. marianum, and almost equal to H15®, a proprietary formulation of B. serrata enriched in AKBA (Glaser et al., 1999) (Fig. 1A).

The apolar fractions of A. ligustica retain—and enhance—the 5-LOX inhibitory activity. This was evident after L/L fractionation of the crude methanol extract of A. ligustica, with the hexanic fraction resulting highly active, and the dichloromethane fraction being of similar activity to H15® (Fig. 1B). Previous works showed that these apolar extracts may contain alkamides, which are reported to be good inhibitors of both COX and 5-LOX in vitro (Muller-Javic et al., 1994) and volatiles (Bader et al., 2007). Still we should not dismiss a contribution of more polar sesquiterpene lactones and flavonoids present in the crude extract which are also characteristic of Achillea species (Bruno, 1988; Tzakou et al., 1995).

**CONCLUSION**

We here demonstrate that the simultaneous, acute, direct inhibition of 5-LOX and COX-1 enzymatic pathways, complemented with an anti-inflammatory activity at the level of the NFkB in the case of the Asteraceae, is an important mechanism underlying the popular use of reported antipsoriatic plant species in Southern Italy. A. ligustica, A. arborescens and A. mollis are of particular interest as they also enhance the biosynthesis of 15(S)-HETE—an antiinflammatory eicosanoid. The crude and apolar extracts of A. ligustica were more active as 5-LOX inhibitors than pharmacopoeial and proprietary extracts of reference in the phytotherapy of psoriasis, making them potential active ingredients for future formulations of novel anti-psoriatic herbal medicinal products.

**Acknowledgements**

Dr Bader performed a short research stay in the School of Pharmacy, University of Valencia sponsored by a collaboration agreement (‘convenio’) between the University of Pisa and the University of Valencia. The participation of Ms Francesca Martini was sponsored by the European exchange program SOCRATES.

**Conflict of Interest**

The authors have declared that there is no conflict of interest.

**REFERENCES**

Amenta R, Camarda L, Di Stefano V, Lentinì F, Venza F. 2000. Traditional medicine as a source of new therapeutic agents against psoriasis. *Fitoterapia* 71: S13–S20.

Ammon HPT, Safayhi H, Mack T, Sabieraj J. 1993. Mechanism of antiinflammatory actions of curcumin and boswellic acids. *J Ethnopharmacol* 38: 105–112.

Bader A, Panizzi L, Cioni P, Flamini G. 2007. *Achillea ligustica*: composition and antimicrobial activity of essential oils from the leaves, flowers and some pure constituents. *Cent Eur J Biol* 2: 206–212.

Brand-Williams W, Cuvelier ME, Berset C. 1995. Use of a free radical method to evaluate antioxidant activity. *Lebensm Wiss u Technol* 28: 25–30.

Bremner P, Tang S, Birkmayer H, et al. 2004. Phenylpropanoid NF-kappaB inhibitors from *Bupleurum fruticosum*. *Planta Med* 70: 914–918.

Bruni A, Ballero M, Poli F. 1997. Quantitative ethnopharmacological study of the Campidano Valley and Urzulei district, Sardinia, Italy. *J Ethnopharmacol* 57: 97–124.

Bruno MW, H. 1988. Guaianolides and other constituents of *Achillea ligustica*. *Phytochemistry* 27: 1871–1872.

Charlier C, Michaux C. 2003. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. *Eur J Med Chem* 38: 645–659.

Dehmlow C, Murawski N, de Groot H. 1996. Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. *Life Sci* 58: 1591–1600.

DiSepio D, Chandraratna RA, Napal S. 1999. Novel approaches for the treatment of psoriasis. *Drug Disc Today* 4: 222–231.
Flora K, Hahn M, Rosen H, Benner K. 1998. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 93: 139–143.

Glas T, Winter S, Groscurth P, et al. 1999. Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Br J Cancer 80: 756–765.

Henke D, Danilowicz R, Eling T. 1986. Arachidonic acid metabolism by isolated epidemal basal and differentiated keratinocytes from the hairless mouse. Biochim Biophys Acta 876: 271–279.

Iversen L, Kragballe K. 2000. Arachidonic acid metabolism in skin health and disease. Prost Oth Lipid Med 63: 25–42.

Luper S. 1999. A review of plants used in the treatment of liver disease: part two. Alt Med Rev 4: 178–188.

Safayhi H, Sailer ER, Ammon HP. 1995. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol Pharmacol 47: 1212–1218.

Serhan CN, Chiang N, Van Dyke TE. 2008. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nature Rev Immunol 8: 349–361.

Spector AA, Gordon JA, Moore SA. 1988. Hydroxyeicosatetraenoic acids (HETEs). Prog Lipid Res 27: 271–323.

Sun YP, Oh SF, Uddin J, et al. 2007. Resolvins D1 and its aspirin-triggered 17R epimer. Stereocchemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem 282: 9323–9334.